Our Parliamentary Affairs and Policy and Evidence teams have submitted their calls to the Government as part of the feedback process for the Spending Review.
As the Company transitions to a new organizational structure, the role of Chief Operating Officer ... she led the CMC strategy for the accelerated development of sotatercept (marketed as WINREVAIR) ...
One of its newest products, Winrevair, a treatment for pulmonary arterial hypertension, earned approval last year and should go on to generate over $1 billion in annual sales. Merck should succeed ...
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $118.00. Daina Graybosch has ...
Winrevair (sotatercept), a treatment for pulmonary arterial hypertension (PAH), has emerged as a promising candidate with the potential to reshape the PAH treatment landscape. Analysts are eagerly ...
Recent developments in Merck's pipeline have drawn considerable attention from investors and analysts. Winrevair (sotatercept), a treatment for pulmonary arterial hypertension (PAH), has emerged as a ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback